Lakeside Holding (LSH) is pleased to announce that through its wholly-owned subsidiary, Sichuan Hupan Jincheng Enterprise Management Co., has entered into an equity transfer agreement to acquire Hupan Pharmaceutical, gaining entry into the medical logistics sector. The acquisition, valued at $0.6M, is anticipated to deliver approximately $7M of annual revenues to Lakeside. Founded in May 2024 and headquartered in Wuhan, Hupan Pharmaceutical is a comprehensive pharmaceutical distribution and supply chain service provider with verticals in brand promotion and healthcare technology support. Hupan Pharmaceutical is licensed for drug wholesale, retail, and third-class medical device distribution in China, with recent expansion to include refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LSH:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
